According to filings with the U.S. Securities and Exchange Commission, Alimera Sciences is raising $27,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Richard Eiswirth played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Alimera Sciences
Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. Welcome to Alimera. We’re Glad You’re Here. We are a company of people with a passion for protecting the retina to preserve vision. Every day we have the opportunity to change a life, so we use our knowledge, innovative treatments and collaboration with providers, patients and partners to get it done. Retinal disease is our focus. Why? Because we’re passionate about the retina as it enables us to see our world, converting light to images in our brain. And we believe that diseases of the retina are not well treated with current therapies and will affect millions of people in aging populations. We See More, Together. We see more opportunity for innovative, vision-improving treatments to help patients see more. We see more positive outcomes in collaboration with providers. We see more as an organization — one of us is never as valuable as ALL of us.

To learn more about Alimera Sciences, visit http://alimerasciences.com/

Contact:
Richard Eiswirth, Chief Executive Officer
678-990-5740

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.